University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > HIV Meds Updates
Updated Occupational PEP Guidelines
Related Resources
ARV Profiles
ARV Charts & Tables
Drug Interactions

Updated guidelines for management of occupational exposures to HIV were published by the U.S. Public Health Service in September.

Among many important recommendations, the new guidelines:

Eliminate assessment of exposure severity as a means of determining the number of PEP drugs
Recommend PEP regimens consisting of at least 3 ARVs for all exposed persons
Recommend newer ARVs as "preferred" and "alternative" regimens for occupational PEP
Raltegravir + tenofovir DF/emtricitabine (Truvada) is the "preferred" HIV PEP regimen
Strongly emphasize the importance of ARV tolerability and convenience (eg, once-daily dosing, few pills) to enhance adherence
Strongly emphasize the importance of monitoring for adverse effects and otherwise supporting exposed persons to complete 28 days of PEP
Discuss the use of 4th-generation HIV Ag/Ab assays for follow-up testing: if these are used, testing can be concluded 4 months after exposure (as opposed to 6 months with other HIV antibody assays)
Recommend expert consultation for all HIV exposures

New guidelines for management of nonoccupational exposures are under consideration.

Reference
Kuhar DT, Henderson DK, Struble KA, et al; U.S. Public Health Service Working Group. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. Infect Control Hosp Epidemiol. 2013 Sep;34(9):875-92.